Rapid Micro Biosystems, Inc.

In September 2017, the Company’s Board of Directors and principal investors (including representatives from EDBI, KPCB Holdings, Longitude Capital, Quaker Bioventures, TPG, and TVM Capital) approved the Singapore Financing Pathway.

‍

• In April 2020, the Company announced it has received $120 million in funding from a group of investors led by Ally Bridge
• Rapid Micro announced the Nephron 503(b) Outsourcing division will deliver critical medical supplies using Growth Direct™.
• Third500 was in the process of a successful syndication of the Pre-IPO when Bain offered a $60MM term sheet for the private round.\
• Xeraya committed $10 million as part of a $30MM Pre-IPO. In parallel to the Pre-IPO, the Company was entertaining selected interest from US investors for the second tranche of a Series B “restructuring / recapitalization”, which had been initiated by selected Insiders in November 2017.